Year: 2019
Type: erratum
Abstract: This erratum corrects “Oracle or false prophet? Can we predict AAV efficacy based on preexisting antibody titers?” by Xavier M. Anguela and Katherine A. High, which published in Research and Practice in Thrombosis and Haemostasis Vol. 3, No. 2, pp. 149-151, 2019. https://doi.org/10.1002/rth2.12190. On page 150, a sentence reads “ln this regard, use of assays that do not rely on transduction performance, such as total antibody assays or the assay recently developed by Guo and colleagues, which relies on quantification of AAV binding to the target cells in vitro using a qPCR assay.19” It was meant to read, “ln this regard, use of assays that do not rely on transduction performance, such as total antibody assays or the assay recently developed by Guo and colleagues, which relies on quantification of AAV binding to the target cells in vitro using a qPCR assay,19 might provide a potential advantage.” The publisher apologizes for this error.
DOI: 10.1002/rth2.12247
Language: English
Subfield: Genetics
Domain: Life Sciences
Keywords: adeno-associated virus, gene therapy
Open Access status: gold
Estimated APC paid: $2,000
OpenAlex ID: W4229690337
